Work

Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.2545

Authors: Kyriakos P. Papadopoulos, Anthony W. Tolcher, Amita Patnaik, Drew Warren Rasco, Glenda Chambers, Murali Beeram, Ronald Savage, Terence Hall, Brian E. Schwartz, Julia Kazakin, Patricia LoRusso

Institutions: South Texas Accelerated Research Therapeutics, Arqule (United States), Yale Cancer Center

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921376911

Cites:

Cited by: 8

Related to: 10